|
Product complaint # (b)(4).This is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Additional information was requested, and the following was obtained via: could you please clarify if the issue was related to the surface of the suture? or [ans: surface of the suture].Did the issue was breakage needle? [ans: no].Please provide more details about the issue? [ans: surgeons experienced the barbs are smaller than usual (the previous lot).They would like to investigate the strength and barbs size of this batch of stratafix suture].Could you please confirm how many devices present the issue? [ans: 4 pcs].Could you please confirm if the patient suffer from any sign or consequence due to the issue? please provide more details [ans: unknown] did any dehiscence present to the patient? please clarify [ans: no].Device analysis: the product was returned for evaluation.Visual inspection evaluation was conducted on the returned device.Visual analysis of the returned sample determined that one sealed packet that pertains to product code sxpp1b421 was received for evaluation, in order to evaluate the condition of the returned samples, the packet was opened, and the swage and attachment area was noted as expected.The suture was examined, and the barbs were present along the strand; also, 10 barbs were measured, and all barbs met with the requirements.In addition, the loops were as expected.As part of quality process, all devices are manufactured, inspected, and released to approved specifications.There may have been other circumstances or issues that occurred during the use of the device that we were unable to duplicate during our laboratory analysis.Additional complaint information monitoring for potential safety signals is conducted through complaint trending as part of post-market surveillance.A manufacturing record evaluation was performed for the finished device batch sebcpq , sxpp1b421 and no non-conformances were identified.Trade name - irgacare®.Active ingredient(s) ¿ triclosan.Dosage form ¿ suture/solid/parenteral.Strength ¿ = 2360 ¿g/m.Events reported: 2210968-2022-08445, 2210968-2022-08446, 2210968-2022-08448.
|